-
New insights into the pathophysiology of inflammatory bowel diseases like Crohn’s using mouse model and lab-grown organoids.
Medical Mythbusting Commentary for August 28, 2026 Source:Crohn’s breakthrough? Your gut may never forget inflammation, Israeli scientists find
-
Study in Nature Communications reports that dietary feeding of phosphatidylcholine or its precursor choline restored more youthful mitochondrial structure and function in worm and human cell culture models restoring more youthful function.
Medical Mythbusting Commentary for August 18, 2026 Source:Scientists Uncovered a Hidden Switch Inside Our Cells That Could Slow—or Even Reverse—Aging Reference:Aging-associated decline of phosphatidylcholine synthesis is a malleable trigger of natural mitochondrial aging
-
This new Alzheimer’s drug targets a different brain protein, and requires further evaluation in the research timeline. Further studies required including phase 3 data.
Medical Mythbusting Commentary for July 16, 2026 Source:This new Alzheimer’s drug targets a different brain protein, and is showing promise
-
Reports of data manipulation of Tavneos efficacy leads to retraction of study by the New England Journal of Medicine and advisory from Health Canada.
Medical Mythbusting Commentary for July 10, 2026 Source:Health Canada warns doctors not to start this prescription medication Colby Cosh: The drug that was approved on fake data
-
Genetic/molecular mechanism discovered to explain why heart muscle does not develop cancer or at least rarely does so.
Medical Mythbusting Commentary for June 29, 2026 Source:Why Does the Heart Rarely Develop Cancer?
-
New medication for the treatment of advanced pancreatic cancer increases median overall survival from 6.7 to 13.2 months.
Medical Mythbusting Commentary for June 1, 2026 Source:‘I actually started crying’: Oncologist reacts to pancreatic cancer drug results Synopsis of the article and study: Benefits: Doubled survival, oral convenience, targeted action, manageable side effects. Limitations: Grade 3+ adverse events in about one-third of patients; still experimental, not yet fully approved; tested in advanced cases post-chemo.
-
Mouse model demonstrates that using microRNA via nasal spray reverses some of the inflammatory processes that contribute to brain aging and cognitive decline. Many years to go to determine if safe and efficacious for people.
Medical Mythbusting Commentary for May 28, 2026 Source:Scientists say they’ve reversed brain aging with a simple nasal spray Reference: Intranasal Human NSC‐Derived EVs Therapy Can Restrain Inflammatory Microglial Transcriptome, and NLRP3 and cGAS‐STING Signalling, in Aged Hippocampus
-
Beta-blockers, taken by millions after a heart attack, found to be ineffective for people with uncomplicated heart attacks (normal heart function thereafter) and presents increased risk of harm to women. Changes to management likely in the works for this population.
Medical Mythbusting Commentary for May 27, 2026 Source:Common heart drug taken by millions found useless — and possibly dangerous Reference:Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial
-
Remnant cholesterol levels found to be an independent risk factor for heart disease. We discuss what this is and what the approach to management entails.
Medical Mythbusting Commentary for May 26, 2026 Source:Experts have found a new type of cholesterol. And it could be the most dangerous Reference: Source: openevidence.comRemnant cholesterol — defined as total cholesterol minus LDL-C minus HDL-C — is an emerging and increasingly recognized causal risk factor for ASCVD. Management centers on lifestyle modification as first-line therapy,…